Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322712 · ClinicalTrials.gov registry record
INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
A clinical trial, sponsored by University of New Mexico.
- Terminated
- Registry status
- 12
- Enrollment target
NCT00322712: Clinical Trial study, sponsored by University of New Mexico.
NCT00322712 is a clinical trial that was terminated before completion, run by University of New Mexico. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00322712 was terminated before completion, sponsored by University of New Mexico.
- TERMINATED
- Registry status
- 12 participants
- Enrollment target
Study Summary
Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
Primary Outcome
Length of survival of patients treated with a combination of Oxaliplatin 60mg/m2, Irinotecan 90mg/m2, and Cetuximab 250 mg/m2 delivered every other week.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-01 |
Why NCT00322712 stopped before completion
NCT00322712 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00322712 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00322712 about?
NCT00322712 is a clinical study titled "INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer". Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
What is the current status of trial NCT00322712?
This trial is currently terminated. The enrollment target is 12 participants. The study started on 2006-09. Estimated completion is 2007-01.
Who is sponsoring clinical trial NCT00322712?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia